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APOBEC3G and APOBEC3F exhibit antiretroviral activity primarily as a consequence of their ability to deaminate cytidines in retroviral
DNA. Here, we compare the properties of APOBEC3F and APOBEC3G from human, macaque, and African green monkey (AGM). While all
APOBEC proteins tested exhibited anti-HIV-1 activity, human APOBEC3F was, surprisingly, 10- to 50-fold less potent than human APOBEC3G.
However, similar discrepancies in antiviral potency were not found when pairs of proteins from macaque and AGM were compared. Intrinsic
differences in the ability of each APOBEC protein to induce hypermutation, rather than differences in packaging efficiency, partially accounted for
variable antiretroviral activity. Each of four primate lentivirus Vif proteins reduced human and AGM APOBEC3F expression and antiviral activity,
but all were only partially effective and species-specific effects were relatively minor. Overall, highly efficient and species-specific neutralization
of APOBEC3G, and less efficient neutralization of APOBEC3F, appears to be a general property of Vif proteins.
© 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1; Vif; APOBEC3G; APOBEC3F; HypermutationIntroduction
Intrinsic cellular defenses against retroviral infection include
at least two cytidine deaminases, APOBEC3G and APOBEC3F,
that modify nascent minus-strand retroviral DNA during reverse
transcription (Bishop et al., 2004; Liddament et al., 2004;
Sheehy et al., 2002; Wiegand et al., 2004; Zheng et al., 2004)
The uracil-containing minus-strand DNA that results from
deamination is either degraded, presumably due to recognition
by cellular DNA repair enzymes, or survives to become
integrated into the host genome in a hypermutated form (Harris
et al., 2003; Lecossier et al., 2003; Mangeat et al., 2003; Yu et
al., 2004b; Zhang et al., 2003). Although cytidine deamination
occurs during the early phases of the retrovirus life cycle,
antiviral acti vity is observ ed as a consequ ence of the p ackaging
of cytidine deaminases into viral particles during assembly.
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doi:10.1016/j.virol.2005.12.035packaging requires nucleocapsid and RNA but appears to be a
rather nonspecific process, in that it can be packaged into
retroviral particles that bear little or no sequence homology
(Alce and Popik, 2004; Cen et al., 2004; Douaisi et al., 2004;
Khan et al., 2005; Mariani et al., 2003; Schafer et al., 2004;
Svarovskaia et al., 2004; Zennou et al., 2004). Thus, it should be
difficult for retroviruses to acquire resistance to the antiviral
effects of APOBEC3G or APOBEC3F. While murine leukemia
virus appears to have acquired the ability to avoid packaging
murine APOBEC3, this property does not extend to human
APOBEC3G (Doehle et al., 2005a, 2005b), which can be
packaged by all retroviruses that have been examined thus far.
Most lentiviruses counteract APOBEC3G activity by expres-
sing Vif proteins that prevent its incorporation into virions. This
is achieved primarily by inducing its degradation by protea-
somes (Conticello et al., 2003; Kao et al., 2003; Liu et al., 2004;
Marin et al., 2003; Mehle et al., 2003; Sheehy et al., 2003;
Stopak et al., 2003; Yu et al., 2003) and perhaps by additional
mechanisms (Mariani et al., 2003; Stopak et al., 2003).
Human APOBEC3G and APOBEC3F differ slightly in their
substrate preference (Bishop et al., 2004; Liddament et al.,
2004; Wiegand et al., 2004; Zheng et al., 2004). For human
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appears to be most efficient if another cytidine is present at the-1
position relative to the deaminated base. Thus, the principal
effect of APOBEC3G mutagenesis of nascent retroviral DNA
during reverse transcription is the accumulation of G-to-A
mutations on the plus-strand, in the context of GG dinucleotides
(which are changed to AG). However, mutations in other
contexts, particularly GA-to-AA, also occur at lower frequency.
Conversely, human APOBEC3F deamination is more efficient
if a thymidine is present at the −1 position, and therefore, the
‘footprint’ of APOBEC3F mutagenesis is primarily GA to AA
substitutions. Aside from their distinguishable substrate speci-
ficities, other reported differences between human APOBEC3G
and APOBEC3F proteins are the potency with which they
inhibit HIV-1 infectivity and in their relative sensitivity to HIV-
1 Vif. Specifically, human APOBEC3F has been reported to be
marginally less inhibitory and marginally less sensitive to HIV-
1 Vif than is APOBEC3G (Liddament et al., 2004; Wiegand et
al., 2004).
While human, macaque, and AGM APOBEC3G proteins
have each been shown to reduce the infectivity of human,
macaque, and AGM lentiviruses, they differ markedly in their
propensity to be excluded from virions by certain Vif proteins
(Mariani et al., 2003). In particular, HIV-1 and SIVAGM Vif
proteins act specifically on APOBEC3G proteins from the
species in which the parental virus is found, but HIV-1 Vif is
ineffective against AGM APOBEC3G and SIVAGM Vif is
ineffective against human APOBEC3G (Mariani et al., 2003). A
single amino acid difference at position 128 of the human and
AGM APOBEC3G proteins is a critical determinant of this
difference (Bogerd et al., 2004; Mangeat et al., 2004;
Schrofelbauer et al., 2004; Xu et al., 2004). The resistance of
human APOBEC3G to SIVAGM Vif may, in part, be responsible
for the failure of SIVAGM strains, which are highly prevalent in
relatively abundant African primates, to colonize humans.
Conversely, Vif proteins from the HIV-2/SIVMAC/SIVSM
primate lentivirus lineage appear somewhat more promiscuousFig. 1. Alignment of APOBEC3F amino acid sequences from human CEM cells (Hu)in that they are active against both human and AGM
APOBEC3G proteins (Bogerd et al., 2004; Schrofelbauer et
al., 2004). Perhaps as a result, viruses from this lineage are able
to replicate efficiently in at least four relatively divergent
primate species, namely sooty mangabeys, macaques, baboons,
and humans.
Thus, while APOBEC3G and APOBEC3F are known to be
inhibitors of primate lentivirus replication and APOBEC3G
has clear species-specific properties that likely affect the
ability of lentiviruses to cross-species, there has been no
previous characterization of nonhuman primate APOBEC3F
proteins. Therefore, to determine whether species-specific
differences in APOBEC3F might contribute to species-specific
primate lentivirus tropism, we compared the anti-HIV-1
activity and Vif sensitivity of human, rhesus macaque, and
AGM APOBEC3F and APOBEC3G proteins. We found
surprising species-specific differences in the relative potency
with which APOBEC3F and APOBE3G inhibited HIV-1
infectivity. Conversely, the marked species-specific differences
in the sensitivity of APOBEC3G proteins to primate lentivirus
Vif proteins were much less evident when APOBEC3F
proteins were compared. Thus, in the case of humans, rhesus
monkeys, and AGMs, APOBEC3F appears a significantly less
potent barrier to cross-species transmission than does
APOBEC3G.
Results
APOBEC3F from macaques and African green monkeys
cDNAs encoding APOBEC3F were amplified from a human
cell line (CEM), a rhesus macaque cell line (221), and an AGM
cell line (CV-1). An alignment of the amino acid sequences that
these cDNAs encode is shown in Fig. 1. Macaque and AGM
APOBEC3F proteins were 93% identical to each other, and
87% and 88% identical to human APOBEC3F respectively.
Sequence differences among the APOBEC3F variants were, rhesus macaque 221 cells (Mac), and African green monkey CV1 cells (AGM).
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important variation among primate APOBEC3G sequences
occurs at amino acid position 128, where an aspartate in human
APOBEC3G and lysine in macaque and AGM APOBEC3G
defines the differential sensitivity of the APOBEC3G proteins
to the Vif proteins of HIV-1 and SIVAGM (Bogerd et al., 2004;
Mangeat et al., 2004; Schrofelbauer et al., 2004; Xu et al.,
2004). Notably, in human, macaque and AGM APOBEC3F
proteins, the analogous residue (position 127) is a conserved
glutamate.
Comparison of the anti HIV-1 potency of human, macaque, and
AGM APOBEC3G and APOBEC3F proteins
Previously, it has been shown that both human APOBEC3G
and APOBEC3F proteins inhibit the infectivity of HIV-1 when
expressed in virus producing cells. Some studies suggest that
human APOBEC3F may be a marginally less potent inhibitor
of HIV-1 infectivity than is human APOBEC3G (Liddament et
al., 2004; Wiegand et al., 2004). We compared the degree to
which APOBEC3G and APOBEC3F from humans, macaques,
and African green monkeys inhibited HIV-1 infectivity, over a
range of APOBEC protein expression levels. Varying amounts
of each APOBEC3G or APOBEC3F expression vector were
cotransfected with plasmids expressing HIV-1 Gag-Pol, a
packageable HIV-1 vector genome, which expressed the HIV-1
Tat protein, and a VSV-G envelope. To facilitate comparison of
expression levels of APOBEC3G and APOBEC3F, each
protein carried an amino terminal myc-epitope tag. None of
APOBEC3G or APOBEC3F proteins affected the level of
synthesis or release of the HIV-1 Gag proteins (data not shown
and see Fig. 3, below), but as can be seen in Fig. 2A, human
APOBEG3G was an extremely potent inhibitor of HIV-1
infectivity, and reduced it to virtually undetectable levels at the
highest dose of expression plasmid tested. Human APO-
BEC3F, while clearly an inhibitor of HIV-1 infectivity, reduced
HIV-1 infectivity 10- to 50-fold less efficiently than humanFig. 2. Comparison of antiviral potency and expression levels of APOBEC3G and A
from human, macaque, and AGM, as indicated, on HIV-1 infectivity. HIV-1 vector p
myc-tagged APOBEC3F (closed symbols) or APOBEC3G (open symbols) expressio
absence of APOBEC expression (typically 50,000 to 150,000 relative light units (RL
for β-galactosidase. The values plotted are the mean ± standard deviation of 3 assay p
background was typically around 50 RLU. (B) Analysis of human (Hu) macaque (Ma
of cells transfected with HIV-1 vector expression plasmids, in the absence of Vif,
transfected cells were subjected toWestern blot analysis using an α-myc monoclonal a
reactive band (ns) are indicated.APOBEC3G at sub-saturating levels of APOBEC expression
(Fig. 2A).
Interestingly, the same situation did not apply when macaque
and AGM APOBEC3G and APOBEC3F proteins were
compared. Specifically, macaque and AGM APOBEC3F
proteins were slightly more potent inhibitors than were the
corresponding APOBEC3G proteins (Fig. 2A). These differ-
ences between species were largely, but not exclusively, the
result of differential potencies among the APOBEC3G proteins.
Indeed, human APOBEC3G was about 50- to 100-fold more
potent than macaque or AGM APOBEC3G at sub-saturating
levels of inhibition (Fig. 2A). Conversely, when the three
APOBEC3F proteins were compared, macaque APOPEC3F
was found to be somewhat more inhibitory than human or AGM
APOBEC3F.
Importantly, these differences in anti-HIV-1 activity were not
due to differences in expression level. As can be seen in Fig. 2B,
the various amino terminally tagged APOBEC3G and APO-
BEC3F proteins were expressed at approximately equivalent
levels when the same amount of expression plasmid was
transfected. Very minor variations in expression level did not
correlate with antiviral potency.
Packaging of APOBEC3G and APOBEC3F proteins into
HIV-1 particles
To attempt to explain the variation in the potency with which
the various APOBEC3F and APOBEC3G inhibited HIV-1
infectivity, we first compared the efficiency with which they
were packaged into HIV-1 particles. AWestern blot analysis of
cells expressing the HIV-1 Gag-Pol and the various myc-tagged
APOBEC3G and APOBEC3F proteins is shown in Fig. 3A, and
a corresponding analysis of the resulting virus-like particles is
shown in Fig. 3B. An irrelevant, N-terminally myc-tagged
protein (GFP) that was not expected to be packaged into virion
particles was included in the experiment as a control. As can be
seen in Fig. 3B, each of the APOBEC3G and APOBEC3FPOBEC3F from human macaque and AGM. (A) Effects of APOBEC proteins
articles were generated in the presence of the indicated amount of cotransfected
n plasmid. Infectivity is plotted as a value relative to what was observed in the
U)) and was measured using TZM-bl target cells and a chemiluminescent assay
oints and are representative of at least three independent experiments. The assay
c) and AGMAPOBEC3F (3F) and APOBEC3G (3G) expression levels. Lysates
and 100 ng of myc-tagged APOBEC expression plasmids, as well as mock-
ntibody. The migration positions of the APOBEC proteins and a non-specifically
Fig. 3. Analysis of APOBEC3F and APOBEC3G packaging. Cells were
transfected with HIV-1 vector expression plasmids and myc-APOBEC
expression plasmids (3G or 3F, as indicated), or a myc-GFP expression plasmid
as a control (−). Lysates of transfected cells (A), or virions (B) harvested by
ultracentrifugation, were subjected to Western blot analysis using a α-p24
(upper panels) or α-myc (lower panels) monoclonal antibodies. The migration
positions of the myc-tagged APOBEC and GFP proteins are indicated.
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HIV-1 particles. In general, each of the APOBEC3F proteins
was packaged with similar efficiency. However, APOBEC3F
proteins were somewhat more efficiently packaged than were
APOBEC3G proteins. This was particularly evident in the case
of the AGM proteins, where APOBEC3G was apparently less
well packaged than the other APOBEC3G proteins and
significantly less so than AGM APOBEC3F (Fig. 3B).Fig. 4. Reversal of APOBEC-mediated infection inhibition by Vif proteins. Effects o
infectivity in the presence of APOBEC3F (A) or APOBEC3G (B). HIV-1 vector partic
tagged APOBEC3F or APOBEC3G expression plasmid and a fixed quantity (100 ng)
was measured using TZM-bl target cells and a chemiluminescent assay for β-galacto
assay points and are representative of at least three independent experiments.Relative sensitivity of APOBEC3G and APOBEC3F proteins to
Vif
APOBEC 3G proteins are degraded as a consequence of their
recruitment to a Cul5/ElonginB/ElonginC/Rbx1 complex by
Vif (Yu et al., 2003). The relative sensitivity of APOBEC3G
proteins to Vif mediated degradation differs markedly according
to the source of the APOBEC3G and Vif and is largely defined
single amino acid residue (aspartate or lysine) at position 128 in
APOBEC3G (Bogerd et al., 2004; Mangeat et al., 2004;
Schrofelbauer et al., 2004; Xu et al., 2004). Because the
equivalent position is occupied by a conserved glutamate in
APOBEC3F proteins (Fig. 1) and sequences surrounding this
amino acid in APOBEC 3F are more closely related to
APOBEC3B (which is Vif-resistant in humans (Bishop et al.,
2004; Doehle et al., 2005a, 2005b; Yu et al., 2004a)) than to
APOBEC3G, we next determined whether the highly species-
specific anti-APOBEC3G activity exhibited by Vif proteins
would also be observed when APOBEC3F was the Vif target
protein.
A general observation was that Vif proteins tended to be less
effective at counteracting the antiviral effect of APOBEC3F
than that of APOBEC3G. This finding has been noted
previously in analyses of human APOBEC proteins and HIV-
1 Vif (Liddament et al., 2004; Wiegand et al., 2004), but Fig. 4A
shows that this property is quite marked and extends to
nonhuman primate APOBEC3F proteins and other lentiviral Viff Vif proteins from HIV-1, HIV-2, SIVMAC, and SIVAGM, as indicated, on HIV-1
les were generated in the presence of the indicated amount of cotransfected myc-
of each Vif expression plasmid. Infectivity, plotted as relative light units (RLU),
sidase activity. The values plotted are the mean ± standard deviation of duplicate
Fig. 5. Depletion of APOBEC3F and APOBEC3G as a consequence of Vif
protein expression. Effects of Vif proteins from HIV-1, HIV-2, SIVMAC, and
SIVAGM, as indicated, on human (Hu) macaque (Mac) or AGMAPOBEC3F (A)
or APOBEC3G (B) levels in cell lysates. Cells were transfected with HIV-1
vector expression plasmids, 100 ng of myc-tagged APOBEC expression
plasmids, and 100 ng of each Vif expression plasmid. Lysates of transfected cells
were subjected to Western blot analysis using an α-myc monoclonal antibody.
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the Vif proteins tested except that of HIV-2ROD, irrespective of
macaque APOBEC3F expression level. The infectivity defect
induced by human and AGM APOBEC3F proteins was partly
reversible by Vif proteins, and there was some degree of
differential specificity: human APOBEC3F antiviral activity
was somewhat inhibited by, in order of decreasing potency,
HIV-2, SIVMAC, HIV-1, and SIVAGM Vif, while AGM
APOBEC3G antiviral activity was reduced by, in order of
decreasing potency, SIVAGM, HIV-2, HIV-1, and SIVMAC Vif
(Fig. 4A). Attempts to map a discrete APOBEC3F determinant
of differential sensitivity of to HIV-1 Vif were unsuccessful, due
to the rather marginal differences in Vif sensitivity among
APOBEC3F proteins and variable activity of the human/
macaque APOBEC3F chimeras, but these experiments hinted at
the involvement of more than one determinant (data not shown).
The ability of Vif to reverse APOBEC3F-induced infectivity
defects was dependent on the latter's expression level. Under
conditions where sufficient APOBEC3F was expressed to
induce only a 10-fold reduction in HIV-1 infectivity, then the
majority of this infectivity could be recovered by expression of
one or more of the Vif proteins (Fig. 4A). However, when the
levels of APOBEC3F were increased so as to induce a larger
(100-fold or more) infectivity defect, then only about one tenth
to one fifth of the infectivity could be recovered by expression
of even the most potent Vif proteins (Fig. 4A). This situation
contrasted markedly with that observed when HIV-1 infectivity
was inhibited by APOBEC3G proteins under otherwise
identical assay conditions. In this case, and as can be seen in
Fig. 4B, the Vif proteins appeared significantly more potent and
specific in their ability to abolish infectivity defects induced by
the three different APOBEC3G proteins. For example, a N100-
fold infectivity defect induced by human APOBEC3G was
almost completely reversed by HIV-1, HIV-2, and SIVMAC Vif
proteins but was completely unaffected by SIVAGM Vif. Only at
the highest level of human APOBEC3G expression (where
infectivity was reduced to undetectable levels in the absence of
Vif) were the active Vif proteins incompletely able to restore
infectivity (Fig. 4B). Even though macaque and AGM
APOBEC3G differ from human APOBEC3G in that they are
almost entirely insensitive to HIV-1 Vif (Fig. 4B), 100-fold
infectivity defects induced by macaque and AGM APOBEC3G
were completely abolished by the Vif proteins from HIV-2,
SIVMAC, and SIVAGM. Of note, a single dose of Vif expression
plasmid was used throughout these experiments, thus while it is
difficult to compare the expression level of the different Vif
proteins with each other, we can conclude that in every case,
levels of Vif protein that completely restore APOBEC3G
inhibited infectivity, are clearly less effective against APO-
BEC3F inhibition, whether or not the APOBEC3F protein is
derived from the same or a different species.
Effects of Vif proteins on steady-state APOBEC3G and
APOBEC3F levels
We next compared the ability of the various Vif proteins to
reduce the levels of APOBEC3G and APOBEC3F proteins incells producing HIV-1 vector particles. As can be seen in Fig.
5A, each of the Vif proteins reduced the level of, but did not
eliminate, human or AGM APOBEC3F from cells. In contrast,
none of the Vif proteins, with the exception of HIV-2-Vif, had
any effect on the levels of macaque APOBEC3F in cell lysates.
While the degree to which each Vif protein reduced
APOBEC3F expression levels and enhanced HIV-1 infectivity
correlated imperfectly, the ability of Vif proteins to reduce
APOBEC3F levels did predict their ability to partly restore
HIV-1 infectivity. In particular, the macaque APOBEC3F
protein was resistant to most of the Vif proteins in both Western
blot and infectivity assays (compare Figs. 5 and 4).
Again, the effects of the Vif proteins on APOBEC3G levels
in cells were quite different and correlated well with their effects
on HIV-1 infectivity. Specifically, human APOBEC3G levels in
cells were dramatically reduced by HIV-1, HIV-2, and SIVMAC
Vif but were unaffected by SIVAGM Vif. In contrast, macaque
and AGM APOBEC3G proteins were largely resistant to HIV-1
Vif but were virtually eliminated from cells by HIV-2, SIVMAC,
and SIVAGM Vif proteins. Thus, Vif proteins eliminated
APOBEC3G proteins from cells with greater potency and
specificity than they did APOBEC3F.
Mutational burden and profile induced by primate APOBEC3G
and APOBE3F
To attempt to explain differences in the potency with which
APOBEC proteins inhibited HIV-1 vector infectivity and why
APOBEC3G appears, in general, to be a preferred target for Vif
proteins, we next compared the burden and profile of mutations
induced by APOBEC3G and APOBEC3F from the three
species. To accomplish this, we generated VSV-G pseudotyped
HIV-1 particles using a cell line carrying an integrated HIV-1/
hrGFP vector. DNA was extracted from cells that were
inoculated with these particles, and hrGFP sequences were
amplified using primers targeted to G-poor sequences. By using
this approach, the target sequence for PCR amplification is
absent from the transiently transfected DNA used to generate
virions and is only present as integrated copies in the HIV-1
vector particle producing cells. Thus, contaminating ‘input’
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subsequently harvested from target cells and used in the PCR
reactions. Indeed, as can be seen in Fig. 6A, most sequences
generated from nascent HIV-1 DNA in the presence of an
APOBEC3 protein carried 1 or more G-to-A substitutions.
Conversely, 0/10 sequences generated in an otherwise equiv-
alent way but the absence of an APOBEC3 protein carried G-to-
A substitutions (data not shown).
The number of mutations generated by the APOBEC3G and
APOBEC3F proteins (Fig. 6) broadly correlated with theFig. 6. Analysis of APOBEC3F and APOBE3G mutagenized hrGFP sequences. (A
APOBEC3F (A) and APOBEC3G (B). Each horizontal line represents an individu
transduced with an HIV-1 vector generated in the presence of the indicated APO
dinucleotide contexts: red = GG-to-AG, cyan = GA-to-AA, green = GC-to-AC, mag
(C, D) Quantitative representation of mutations in hrGFP induced by human, macaqu
an individual hrGFP clone, whose height represents the total number of G-to-A substit
occurred in the context of GG, GA, GC, or GT dinucleotides, as indicated.potency with which they inhibited infectivity (Figs. 2 and 6,
summarized in Table 1). For instance, among the APOBEC3F
proteins, the antiviral activity and the burden of mutations
induced by macaque APOBEC3F were higher than that of, and
induced by, the other two APOBEC3F proteins, which were
approximately equivalent to each other (Figs. 6A, C). As has
previously been reported (Bishop et al., 2004; Liddament et al.,
2004; Wiegand et al., 2004), the target site specificity of
human APOBEC3G and APOBEC3F differs, with GA
dinucleotides being the preferred target for APOBEC3F, B) Overview of mutations in hrGFP induced by human, macaque, and AGM
al clone of a 480 nucleotide hrGFP sequence amplified from cells that were
BEC protein. Colored vertical lines indicate G-to-A substitutions in various
enta = GT-to-AT. Black lines indicate substitutions other than G-to-A mutations.
e, and AGM APOBEC3F (C) and APOBEC3G (D). Each vertical bar represents
utions. Each bar is shaded according to the proportion of the G-to-A substitutions
Table 1
Correlation between overall mutagenic activity and infectivity inhibition by APOBEC3G and APOBEC3F proteins
APOBEC protein Human 3F Macaque 3F AGM 3F Human 3G Macaque 3G AGM 3G
Mutations per sequence a 4.7 ± 4.0 7.6 ± 12.5 4.3 ± 6.2 17.4 ± 3.4 4.9 ± 3.4 2.1 ± 2.0
Fold infectivity reduction b 12.7 ± 2.9 22.9 ± 3.4 14.9 ± 2.2 470 ± 79 17.7 ± 3.9 4.4 ± 0.7
a Mean ± standard deviation of the number of G-to-A changes in the hrGFP clones described in Fig. 6.
b Reduction in infectivity calculated at by comparing infectivity in the absence of APOBEC protein expression with that at sub-saturating doses of APOBEC3F or
APOBEC3G expression plasmid (100 ng per transfection, mean ± standard deviation of triplicate determinations).
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comparison of the mutations induced by the APOBEC3F
proteins from the three different species revealed no obvious
differences in the target sequence specificity among them
(Figs. 6A, C).
Among the APOBEC3G proteins, the human protein was
more mutagenic and more potently inhibited HIV-1 infection
than the macaque protein, which in turn was more mutagenic
and inhibitory than AGM APOBEC3G. Interestingly, the AGM
APOBEC3G protein exhibited a marginally different target
sequence specificity than did the human or macaque equiva-
lents. Indeed, almost all the assayed AGM APOBEC3G-
induced editing events (49 out of 51, or 96%) occurred in the
context of a GG dinucleotide (Figs. 6B, D). Conversely, human
and macaque APOBEC3G appeared somewhat less selective
for GG dinucleotides. In these cases, 39 of 61 (64%) and 102
out of 173 (59%) of the macaque and human APOBEC3G-
induced mutations occurred in a GG dinucleotide context, with
the bulk of the remaining mutations occurring in the context of
GA dinucleotides (Figs. 6B, D). The apparently increased
specificity of AGM APOBEC3G for GG dinucleotides may be
partly due to reduced levels of incorporation into virions (Fig. 3)
and a lower overall level of editing activity. However, this did
not appear to entirely explain this phenomenon, because
individual sequences mutagenized by macaque or AGM
APOBEC3G and containing similar overall numbers of G-to-
A changes were clearly different in terms of the dinucleotides
that were targeted (Fig. 6D).
While there was some correlation between the mutagenic
activity and the antiviral potency of the APOBEC3 proteins, the
two parameters did not appear directly proportional. In
addition, one feature of APOBEC3F-induced mutagenesis
was that the number of mutations carried by individual
sequences appeared somewhat more variable than that carried
by APOBEC3G mutagenized sequences (Fig. 6). This was
particularly noticeable when, for example, sequences mutagen-
ized by macaque APOBEC3F were analyzed. In this sample,
several sequences carried 0, 1, or 2 mutations, while one 480
nucleotide sequence carried no less than 49 mutations. While
some degree of variation would be expected in assays where
virions are generated by transient transfection along with
cytidine deaminase expression plasmids, this extreme degree of
variability in mutational burden among individual clones
contrasted with the sequences mutagenized by, for example,
human APOBEC3G. In this case, individual clones carried a
comparatively reproducible 12 to 24 mutations per sequence.
Potential reasons for this phenomenon are addressed in the
discussion.Discussion
In this study, we undertook a comparative analysis of human
and nonhuman primate APOBEC3G and APOBEC3F, proteins
that appear largely responsible for the cellular antiretroviral
activity that is counteracted by the Vif proteins encoded by
lentiviruses. Several general conclusions could be drawn from
the comparisons made herein. First, APOBEC3F proteins
tended to be slightly more efficiently incorporated into HIV-1
particles than did APOBEC3G proteins. Second, there was
significant variation in the potency with which the various
APOBEC3G and APOBEC3F proteins inhibited HIV-1 infec-
tion. In particular, human APOBEC3G was a significantly more
potent inhibitor than human APOBEC3F. However, this
difference, which is larger than previously reported (Bishop et
al., 2004; Liddament et al., 2004; Wiegand et al., 2004), was not
maintained when pairs of rhesus macaque or AGM APOBE3G
and APOBEC3F proteins were compared. Thus, while
APOBEC3G and APOBEC3F encapsidation efficiency likely
affects the overall level of inhibition observed, the intrinsic
antiviral activity of the various APOBEC proteins varies
considerably and is not simply a function of how much enzyme
is packaged into virions.
There was a correlation between the mutational burden
induced by APOBEC proteins and the potency with which they
inhibited HIV-1 vector infectivity. However, in the case of
human APOBEC3G, the reduction in infectivity appeared
disproportionate to the number of mutations induced, as
compared to the other APOBEC3G and APOBEC3F proteins
(Table 1). Nonetheless, among the proteins examined, human
APOBEC3G was both the most mutagenic protein and the most
potent infection inhibitor. It is likely that reduction in infectivity
is not directly proportional to mutagenic activity, simply
because the probability of any one mutation among a set of
mutations in an individual vector genome causing a ‘lethal’
defect is likely to increase in a non-linear manner with respect to
mutation frequency. Moreover, the substrate preference of the
cytidine deaminase may influence the potency with which
infection is inhibited (see below). Alternatively, the particular
potency of the human APOBEC3G protein may be explained by
the observation that human APOBEC3G can inhibit HIV-1
infectivity even when mutated to a form that has very low or
absent DNA editing activity (Newman et al., 2005).
There are potential caveats in attempting to correlate the
mutational burden observed in this and other studies with
antiviral activity. Specifically, it seems likely that the relative
stability of each nascent viral DNA molecule would be
inversely correlated with the number of deamination events to
Table 2













Gag (GG-to-AG) 81 51 (63%) 9 (11%)
(GA-to-AA) 132 105 (80%) 4 (3%)
Pol (GG-to-AG) 158 116 (73%) 29 (18%)
(GA-to-AA) 254 212 (83%) 11 (4%)
Env (GG-to-AG) 132 97 (73%) 31 (23%)
(GA-to-AA) 202 161 (80%) 14 (7%)
Tat exon 1 (GG-to-AG) 7 7 (100%) 1 (14%)
(GA-to-AA) 16 11 (68%) 1 (14%)
a Open reading frames from HIV-1 NL4-3 were inspected.
b The total number of GG and GA dinucleotides in each ORF is listed.
c Number and percentage of theoretical editing events that generate coding
changes.
d Number and percentage of theoretical editing events that generate new
translation termination codons (invariably TGG [tryptophan] to TAG or TGA).
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sequences may be more difficult to sample and under-
represented in a collection of clones of derived from nascent
viral DNA. Moreover, a notable difference between APO-
BEC3G and APOBEC3F mutagenized sequences was the
degree of variation in the number of mutations observed per
clone. Specifically, this parameter was generally more variable
for APOBEC3F than for APOBE3G mutagenized sequences
(Fig. 6, Table 1). The underlying reason(s) for this phenomenon
are unknown but could, for example, reflect differential
recognition of dTdU versus dCdU containing DNA by repair
enzymes. Such considerations likely affect the frequency with
which cytidine deamination events are detected using sequenc-
ing-based assays.
Another general conclusion was that Vif proteins appeared to
be more potent and specific when APOBEC3G is the target
cytidine deaminase rather than APOBEC3F. This finding
suggests that APOBEC3G imposes a more potent selective
pressure on the evolution of primate lentivirus vif genes than
does APOBEC3F. Indeed, a surprising and extreme example of
this finding was that macaque APOBEC3F appeared completely
resistant to SIVMAC Vif, despite the fact that SIVMAC239 (the
strain from which the SIVMAC Vif protein was obtained) is fully
able to replicate in to cause AIDS in rhesus macaques. Given
these observations, its seems somewhat unlikely that macaque
APOBEC3F imposes a strong negative selective pressure on the
vif gene of SIVMAC in the context of an in vivo infection. Why
Vif proteins appear to have evolved to be more potent and
specific inhibitors of APOBEC3G than APOBEC3F is unclear.
Indeed, naturally occurring HIV-1 sequences appear to bear the
hallmarks of both APOBEC3G and APOBEC3F-induced
mutagenesis, consistent with the observation that both are
expressed in human lymphocytes (Bishop et al., 2004;
Liddament et al., 2004; Wiegand et al., 2004). It is possible
that Vif genesmay be specifically evolved to permit some degree
of mutagenesis by APOBEC3F. Allowing a certain degree of
cytidine deamination by APOBEC3F could facilitate primate
lentivirus replication in vivo, by accelerating the rate of viral
sequence diversification. Indeed, the tendency of APOBEC3F to
target GA dinucleotides rather than the GG dinucleotides
targeted by APOBEC3G could, in principle, make APOBEC3F
mutagenesis more ‘tolerable’ to retroviruses. While a preferen-
tial tolerance of APOBEC3F versus APOBEC3G mutation
mediated during HIV-1 vector transduction is not immediately
obvious (Table 1), our assay of HIV-1 infectivity, as well as those
commonly used in other studies, is generally based on Tat-
induced activation of a reporter gene and so may not entirely
reflect the functional consequences of APOBEC3F and
APOBEC3G mutagenesis in vivo. As can be seen in Table 2, a
theoretical analysis of possible editing sites in various HIV-1
open reading frames is consistent with this notion. Indeed,
inspection of gag, pol, and env, nucleotide sequence in a
prototype HIV-1 strain shows that mutation at GG dinucleotides,
the preferred target of APOBEC3G, leads to the generation to
translation termination codons in 11% to 23% of cases. These
translation termination codons are invariably generated by
APOBEC3G in the context of pre-existing tryptophan codons(TGG to TAG). Because only a subset of these have overlapping
GA dinucleotides, only 3 to 7% of GA-to-AA editing events (as
favored by APOBEC3F) lead to the formation of new stop
codons (TGGA to TGAA), while a high fraction (up to around
80%) leads to amino acid substitutions. Thus, because the
formation of stop codons is more likely to be lethal to a retrovirus
than single amino acid substitutions, then it is plausible that only
partial inhibition of APOBEC3F activity by Vif may be
tolerated, and even beneficial, to primate lentiviruses.
Overall, it seems possible that several properties of
APOBEC proteins, including cell-type-specific expression,
substrate specificity, and their ability to infiltrate retroviral
particles has influenced their antiretroviral potency and the
evolutionary response of primate lentivirus vif genes to cellular
cytidine deaminases. Such considerations could impact the rate
and direction of lentivirus sequence evolution, the propensity of
primate lentiviruses to cross species, and the potential
therapeutic consequences of inhibitors that block interactions
between Vif and APOBEC3G and/or APOBEC3F.
Materials and methods
Expression plasmids
The expression vector pCRV1, which is designed for the
expression of Rev-dependent genes, has been previously
described (Zennou et al., 2004) and was used to express the
Vif proteins of HIV-1NL4-3, HIV-2ROD, SIVMAC239, and
SIVAGMTan. Each of the aforementioned Vif cDNAs was
amplified from the respective proviral plasmids and inserted
into pCRV1 as EcoRI-NotI digested fragments. RNA, extracted
from human CEM cells, rhesus monkey 221 cells and AGM
CV-1 cells was used as a template in RT-PCR reactions to
generate human, rhesus macaque, and AGM APOBEC3F
cDNAs, respectively. Clones of human APOBEC3G have been
described previously (Zennou et al., 2004), and clones of rhesus
monkey and AGM APOBEC3G were a gift from Nathanial
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amplified by PCR using primers based on human APOBEC3G
or APOBEC3F sequence and inserted as NotI-NotI fragments
into the expression vector pCR3.1/myc (Martin-Serrano et al.,
2001) such that each protein was expressed with a myc-epitope
tag appended to its amino terminus. A plasmid expressing HIV-
1 Gag-Pol constructed in the background of pCRV1 has been
previously described (Zennou et al., 2004), and a plasmid
expressing a packageable HIV-1 genome (pV1/hrGFP) was also
constructed. This genome contains all cis-acting HIV-1 RNA
elements required for genome propagation but harbors large
deletions in gag-pol, vpr, and env, completely lacks vif
sequences and expresses hrGFP (Stratagene) in place of Nef
(details of the construction available on request).
Measurement of APOBEC3G, APOBEC3F, and Vif effects on
HIV-1 infectivity
To produce HIV-1 vector particles, 293T cells (approximate-
ly 105/well in 24-well plates) were transfected with 100 ng pf
pCRV1Gag-Pol, 100 ng of pV1/hrGFP, and 50 ng of a VSV-G
expression plasmid. This basic vector particle-generating
transfection mixture was supplemented with 0 ng, 20 ng, 100
ng, or 500 ng of a pCR3.1/myc based APOBEC3G or
APOBEC3F expression plasmid and 100 ng of a pCRV1-
based Vif expression plasmid. In experiments where the Vif was
omitted or, APOBEC3 levels were varied, a corresponding
quantity of empty pCR3.1/myc and or pCRV1 was included so
that each transfection mixture contained equal amounts of
DNA. Forty-eight hours after transfection, supernatants from
transfected cells were clarified by centrifugation. Thereafter, 5
μl or 50 μl of virus containing supernatant was applied to each
well of 96-well plates containing TZM-bl indicator cells
(Derdeyn et al., 2000) which harbor an integrated Tat-
responsive β-galactosidase reporter gene. After a further 48 h,
the TZM-bl reporter cells were lysed, and β-galactosidase
activity in cell lysates was measured using chemiluminescent
assay as previously described (Martin-Serrano et al., 2001).
Western blot analysis of APOBEC3G, APOBEC3F, and HIV-1
Gag expression and packaging into vector particles
At the same time that virus containing supernatants were
harvested (see above), lysates of the transfected 293T cells were
also prepared and subjected to Western blot analysis using the
9E10 (α-myc-tag) monoclonal antibody (Figs. 2B and 4). To
examine APOBEC3G and APOBEC3F packaging (Fig. 3),
transfections were carried out essentially as described above,
except that they were scaled up slightly (approximately 5 × 105
293T cells/well in 6-well plates) to facilitate detection of the
packaged APOBEC3G and APOBEC3F proteins in virion
particles. Supernatants were harvested and cleared by low speed
centrifugation, and virion particles were concentrated by
ultracentrifugation through a 20% sucrose cushion. Virions
and corresponding cell lysates were analyzed by Western
blotting with α-p24 and α-myc antibodies, as previously
described (Zennou et al., 2004).Hypermutation assay
Analysis of APOBEC-mediated hypermutation of the HIV-
1 genome is generally performed using cells transduced with a
supernatant from transiently transfected cells. This supernatant
often contains contaminating plasmid DNA that could be
amplified along with the newly reverse transcribed DNA in the
transduced cells. To avoid this phenomenon, a cell line
harboring an integrated copy of the V1/hrGFP HIV-1 vector
genome was first generated. This was achieved by transducing
293T cells with V1/hrGFP containing HIV-1 vector particles,
followed by single cell cloning of hrGFP-positive cells that
were isolated by FACS sorting. One of the hrGFP-positive cell
lines was transfected with HIV-1 Gag-Pol and VSV-G
expression plasmids, in the presence or absence of plasmids
expressing APOBE3F or APOBEC3G, and the resulting
vector-containing supernatant was then used to transduce
MT4 cells. HIV-1 vector particles generated in this manner
transduced an hrGFP signal almost as efficiently as equivalent
particles generated by including pV1/hrGFP in the transient
transfection mixture. Ten hours after transduction of the MT4
target cells, DNA was extracted from them using a Qiagen
genomic DNA isolation kit and subjected to PCR using
primers directed to hrGFP sequences that were G-poor on the
sense strand, namely AACAACCACGTGTTCACCA (sense),
and GCGGTGCTGGATGAATGG (antisense). The resulting
PCR products were cloned into a plasmid (Zero-blunt kit,
Invitrogen), and a fragment of 480 nucleotides from 10 to 25
independent clones was sequenced for a total of 4800 to
12,000 nucleotides of sequence in each hypermutation assay
(see Fig. 6). Sequences were aligned using CLUSTAL and
analyzed using HYPERMUT (http://hiv-web.lanl.gov/content/
hiv-db/HYPERMUT/hypermut.html) (Rose and Korber, 2000).
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